This article is for education. Management of patients with rare phenotypes is decided by specialist transfusion, haematology and fetal medicine teams, supported by national reference laboratories and rare donor programmes, following national guidance.
Common Rhesus phenotypes are well understood, but rare variants present real challenges in transfusion medicine. Occurring in fewer than 1 in 1000 individuals, they can complicate blood matching and call for specialised management.
Rhnull individuals lack ALL Rh antigens on their red blood cells, earning the designation "golden blood." With fewer than 50 known cases worldwide, this is the rarest blood type known to medical science.
Rh null red cells lack all Rh antigens, so they are compatible with any recipient as far as Rh antigens are concerned. ABO compatibility and any other antibodies still apply. An Rh null person who has made anti-Rh29 needs Rh null red cells; one who has not should still receive Rh null red cells where possible, to avoid forming it.
For a comprehensive deep-dive into Rh null, including detailed genetics and transfusion challenges, see the dedicated article: Rh Null Phenotype.
Rhnull phenotype results from two distinct genetic mechanisms:
Regulator Type: Mutations in the RHAG gene (most common)
Amorph Type: Inactivating mutations in RHCE on a haplotype that already lacks RHD
| Clinical Aspect | Manifestation | Management |
|---|---|---|
| Haemolytic Anaemia | Mild to moderate, compensated | Usually no treatment needed |
| Red Cell Morphology | Stomatocytosis, spherocytosis | Monitor blood counts |
| Osmotic Fragility | Increased | Avoid dehydration |
| Transfusion Risk | Can form anti-RH29 (anti-total Rh) | Rh null red cells where possible; required once anti-Rh29 has formed |
The D-- phenotype (pronounced "D dash dash") expresses only the D antigen, lacking C, c, E, and e antigens. This results from deletion mutations or hybrid genes that disrupt normal RHCE expression.
Expresses very strong D antigen but lacks all RHCE antigens. Can develop anti-Rh17 (anti-Hr0) antibody.
Lacks E and e antigens. Typically forms anti-Rh17 (anti-Hr0) after transfusion or pregnancy.
Individuals with D-- phenotype face severe transfusion limitations:
Partial D variants lack some D epitopes, so carriers can make anti-D against the epitopes they lack. Weak D was classically defined as a complete D antigen at reduced density. Weak D types 1, 2 and 3 behave this way in practice, but some weak D types, such as type 4.2 (DAR), also lack epitopes and are managed as partial D.
| Partial D Type | Population | Clinical Significance |
|---|---|---|
| DVI | European | Most clinically important; can make anti-D |
| DIII | African | Common in African populations |
| DIVa | African | May be missed by some reagents |
| DV | African | Variable expression patterns |
Weak D describes reduced expression of the D antigen, caused by RHD alleles that encode an altered RhD protein. More than 100 weak D types have been described.
Weak D types 1, 2 and 3 account for most weak D in people of European ancestry. Carriers are generally considered not to make alloanti-D, so once RHD genotyping confirms one of these types they are usually managed as D-positive, for transfusion and in pregnancy.
Weak D type 4.2 is also known as DAR. DAR carriers can make alloanti-D, so DAR is managed as partial D: D-negative red cells for transfusion, and anti-D immunoglobulin prophylaxis in pregnancy. DAR is common in people of African ancestry and is often inherited with RHCE*ceAR, which encodes a partial e antigen.
Until the type has been confirmed by genotyping, a woman of childbearing potential with a weak or discrepant D typing should be managed as D-negative. SHOT's 2024 annual report asks transfusion and maternity services to check that women typed as D variant are assigned a D-negative pathway.
Successful management of patients with rare phenotypes requires coordinated approaches involving multiple strategies:
| Programme/Registry | Coverage | Services |
|---|---|---|
| International Rare Donor Panel | Global | Holds rare donor details from 27 contributing countries; maintained by IBGRL, Bristol |
| American Rare Donor Program | USA | Database of more than 59,000 active rare donors (2014 figure) |
| UK Rare Donor Panel | United Kingdom | NHS-coordinated registry |
| Japanese Rare Donor Registry | Japan | Focus on Asian-specific variants |
| ISBT Working Party | International | Standardisation and coordination |
When no compatible blood is available, the decision to transfuse incompatible red cells, and any supporting measures, is made by the clinical team with a transfusion medicine specialist, supported by the national reference laboratory and rare donor programme. Published experience comes mainly from individual case reports.
Pregnancies with clinically significant red cell antibodies are managed by specialist fetal medicine and transfusion teams under national guidance. Monitoring usually combines antibody quantification or titration with middle cerebral artery Doppler ultrasound, and fetal antigen typing from maternal blood where available.
Reference laboratories are central to managing rare phenotypes, providing specialised testing and coordination:
| Test Type | Application | Typical Turnaround Time |
|---|---|---|
| Extended phenotyping | Complete antigen profile | 1-2 days |
| Adsorption/elution | Complex antibody identification | 2-3 days |
| Molecular genotyping | Definitive variant identification | 3-7 days |
| Whole genome sequencing | Novel variant discovery | 2-4 weeks |
| Flow cytometry | Antigen density measurement | 1-2 days |
The following cases are hypothetical, written to illustrate typical challenges. They do not describe real patients.
Situation: 45-year-old Rhnull patient needs cardiac surgery
Challenge: No compatible donors in country
Solution:
Situation: Second pregnancy, high-titre anti-Rh17
Management:
In Vitro Red Cell Production:
Gene Editing:
Artificial Blood Substitutes:
Rare Rhesus phenotypes are demanding to manage and often depend on international cooperation to find compatible blood. Family screening, autologous donation, cryopreservation, and rare donor registries are the main tools, and molecular methods increasingly underpin accurate diagnosis.
Healthcare providers who encounter unusual serological patterns should suspect a rare variant and consult a reference laboratory early. Identifying these patients before a transfusion is urgently needed gives the best chance of sourcing compatible units in time.
↑ Back to Top